

15 December 2023

Notification under s 708A(5)(e) of the Corporations Act

4DMedical Limited ACN 161 684 831 (ASX: 4DX) (**Company**) advises that it has issued 44,303,797 fully paid ordinary shares (**New Shares**) in accordance with the Company's ASX announcement of 11 December 2023 regarding the Company successfully raising a total of \$35 million (before costs) in a placement to institutional, sophisticated and professional investors (**Placement**) by the issue of New Shares at \$0.79 per New Share.

This notice is given by the Company under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

1. The New Shares were issued by the Company without disclosure to investors under Part 6D.2 of the Corporations Act on 15 December 2023.
2. The Company is providing this notice under section 708A(5)(e) of the Corporations Act.
3. As at the date of this notice, the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) sections 674 and 674A of the Corporations Act.
4. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) or 708A(8) of the Corporations Act, which is required to be disclosed by the Company.

This ASX announcement has been authorised for release by the Board of Directors of 4DMedical Limited.

Yours sincerely,
4DMedical Limited



Naomi Lawrie
Company Secretary